Can your genes predict blood thinner effectiveness?

NCT ID NCT03188705

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial investigates whether genetic variations in the CES1 gene influence how the body responds to the blood thinners clopidogrel and aspirin. Healthy Amish adults will take clopidogrel for a week, then a single dose of aspirin, with blood tests measuring platelet function before and after. The goal is to understand how these genetic differences might alter drug effectiveness, which could one day help tailor antiplatelet therapy to individual patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Clopidogrel and aspirin
What this could lead to
If genetic differences are found, it could lead to personalized antiplatelet therapy, improving safety and effectiveness for people with heart disease.
What could go wrong
This is a small, early-phase study in healthy volunteers, so results may not apply to patients with heart disease. Genetic effects may be subtle or not clinically significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTERY OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Amish Research Clinic

    Lancaster, Pennsylvania, 17602, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.